Efficacy and safety of ticagrelor use in pre-hospital setting - 13/01/22
Doi : 10.1016/j.ajem.2021.04.031
Lukasz Szarpak, PhD, MBA a, e, f, ⁎ 
, Tomasz A. Michalski, MD b, Jacek Smereka, PhD, MD c, Aleksandra Gasecka, PhD, MD d, g, Michal Pruc, MS e, Milosz J. Jaguszewski, MD b
, Tomasz A. Michalski, MD b, Jacek Smereka, PhD, MD c, Aleksandra Gasecka, PhD, MD d, g, Michal Pruc, MS e, Milosz J. Jaguszewski, MD b a Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy in Warsaw, Warsaw, Poland
b 1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland
c Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland
d Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
e Polish Society of Disaster Medicine, Warsaw, Poland
f Maria Sklodowska-Curie Białystok Oncology Centre, Białystok, Poland
g 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
⁎Corresponding author at: Institute of Outcomes Research Maria Sklodowska-Curie Medical Academy, Solidarnosci Av. 12, 03-411 Warsaw, Poland.Institute of Outcomes Research Maria Sklodowska-Curie Medical AcademySolidarnosci Av. 12Warsaw03-411Poland
Keywords : Acute coronary syndrome, Prehospital, Antiplatelet treatment, P2Y12, Ticagrelor, Outcome
Le texte complet de cet article est disponible en PDF.
© 2021
Elsevier Inc. Tous droits réservés.
Vol 52
P. 265-266 - février 2022 Retour au numéro
Article précédent
- Daily ED pharmacy rounds reduces length of stay for behavioral health patients boarding in the emergency department
- Joanne C. Routsolias, ThuyAn Le, Trevor J. Lewis, Mark B. Mycyk
- Sporadic Creutzfeldt-Jakob disease
- Parnia Salehi, Mark Clark, Jeffer Pinzon, Abhijit Patil
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?